Abstract  Brain tissue from 25 patients with clinically definite multiple sclerosis (MS) and as controls brain tissue from 36 patients without neurological disease was tested for the presence of human coronaviral RNA. Four PCR assays with primers specific for N-protein of human coronavirus strain 229E and three PCR assays with primers specific for the nucleocapsid protein of human coronavirus strain OC43 were performed. Sporadic positive PCR assays were observed in both patients and controls in some of the PCR assays. However, these results were not reproducible and there was no difference in the proportion of positive signals from the MS patients compared to controls. Evidence for a chronic infection with the human coronaviruses strain 229E or OC43 in brain tissue from patients with MS or controls has not been found in this study.

Keywords  Multiple sclerosis · Coronavirus · Polymerase chain reaction · Brain

Introduction

The cause of multiple sclerosis (MS) is so far unknown, but both heredity and environmental factors are considered important. Environmental factors, especially viruses, have been the subject of extensive research and discussion, but no specific agent has so far been definitely linked to MS [12].

Human coronaviruses are a worldwide cause of the common cold, but are usually not associated with more serious disease in humans [17]. The mouse hepatitis virus, a murine coronavirus, causes a MS-like demyelinating disease in the central nervous system of rodents, and this animal model has been used as a model for MS [9, 27]. Evidence for the presence of coronaviral genes in human brain tissue has been found using polymerase chain reaction (PCR) or in situ hybridization [15, 16, 25]. The aim of this study was to examine brain tissue from Danish MS patients for human coronaviral RNA sequences using reverse transcriptase (RT)-PCR.

Materials and methods

Brain tissue was obtained from 25 patients with clinically definite MS from two Danish tissue collections. Most patients had chronic progressive MS for many years. Data on the age at death was available for 20 patients (median 60 years, range 38–83 years). From the 25 patients with clinically definite MS, specimens from areas with macroscopically visible plaques were sampled from the periventricular mostly white matter. All brain specimens were stored at –70°C before and after RNA extraction. For the older tissue collection the year of death ranged from 1966 to 1981, whereas the newer brain collection was from 1987 to 1990.

As controls, brain tissue was obtained from 36 consecutive routine autopsies. Autopsy of the brain was routinely performed if a patient had shown some clinical signs of possible intracerebral pathology prior to death. The pathological reports were reviewed and no patients had a history of neurological disease. The cerebral lesions were previous cerebral infarction in 2 patients and moderate cerebral arteriosclerosis in 4 patients. Of the controls 27 had normal cerebral pathology. The causes of death were cancer in 13, lower respiratory tract infection in 9, acute myocardial infarction in 10, and pancreatitis in 1 of the controls. The autopsy report was not available from 3 patients.

As positive control cell culture supernatant fluid containing human coronavirus strain 229E (HCV-229E, ATCC VR-740) and strain OC43 (HCV-OC43, ATCC VR-759) were used. HCV-229E was cultured on L-132 cells (ATCC CCL5) at 37°C and the cell supernatant containing a TCID$_{50}$ (50% tissue culture infective dose) of 10$^6$/ml was used as positive control. HCV-OC43 was cultured on HRT-18 cells (ATCC CCL244) at 33°C and the cell supernatant containing a TCID$_{50}$ of 10$^5$/ml was used as positive control.

Extraction of RNA from brain tissue was performed by homogenization in guanidium thiocyanate buffer followed by ultracentrifugation in a cesium chloride (CsCl) step gradient [22]. The
extracted RNA was evaluated by absorption spectrophotometry at 260 and 280 nm, and by RT-PCR specific for myelin basic protein (MBP) mRNA. Samples negative for MBP or with an absorption ratio \(A_{260}/A_{280}\) lower than 1.6 were excluded from further analysis.

Eight primer pairs were used in the present study (Table 1) and combined in eight different RT-PCR assays (Table 2). The sensitivity of the PCR assays were tested by serial dilutions of the viral supernatants containing HCV-229E and HCV-OC43. All PCR reactions were carried out in 100-µl reaction volume and the concentration of primers, DNA-polymerase (AmpliTaq, Perkin Elmer Cetus) and MgCl2 was optimized for each assay. Extensive tables with details of primer combinations and concentrations of reagents are available from the corresponding author on request [6]. For all pre-PCR procedures filter tips and dedicated pipette sets were used. The PCR products were visualized by UV transillumination following electrophoresis on 1.5% agarose and subsequent Southern blot on Nytran filter. The blot was performed as described, with the exception that the setup was inverted [24]. After overnight transfer, the Nytran filter paper was rinsed briefly in 2 × SSC, and nucleic acids were immobilized by baking at 80°C in vacuum for 2 h. Subsequently, the blots were prehybridized at 42°C for 2 h, followed by hybridization overnight with a HCV-229E or HCV-OC43 DNA probe. Stringent washing was performed in SSC buffer (saline sodium citrate) at 70°C. The probes were produced by PCR as described above from the reference strains and labeled with biotin-7-dATP by nick translation (BioNick, Life Technologies, Rockville, USA). Probe detection was performed using the PhotoGene (BioNick) detection kit according to the manufacturer’s instructions. A result was registered positive when a band of the expected size was present after hybridization.

Table 1 Primers used in this study specific for the nucleocapsid protein gene of the human coronaviruses and the human myelin protein gene (MBP myelin basic protein)

| Primer | Sequence (5’–3’) | Bases | GenBank acc. no. |
|--------|-----------------|-------|-----------------|
| Human coronavirus 229E [23] | AGGCAGAACAAATCGAGACAGAG | 498–521 | J04419 |
| CORO1 [25] | AGCCGCAAGAATTCAGAACCAG | 806–783 | |
| CORO2 [25] | AAGCTTTGGGAAATTCGAGGGAAG | 896–982 | |
| CORO4 [25] | TGGTTTCAGCGTGGTAGGGAATT | 1262–1242 | |
| CORO9 [7] | CAGGATCCCCATAAAGATGC | 400–418 | |
| CORO10 [7] | AGAACGAGCAAGACTCTTGGG | 842–823 | |
| E7 [1] | TCTGCCAAAGAGCTTCTTCTG | 819–838 | |
| E9 [1] | AGCATACAGCTGGTTAGGAGG | 1054–1035 | |
| Human coronavirus OC43 [14] | CCCAAGCAAACTGCTACCTCAG | 215–238 | |
| CORO5 [1] | GCAATCCAGAGTGTGTTGAGG | 520–497 | |
| CORO11 [7] | GGATGCCACTAAACCTCAGCAAG | 820–842 | |
| O7 [1] | GGTTGGATCTGCGAAGATGG | 1035–1014 | |
| Human MBP [27] | AGAACGAGCAGACTCTCAG | 87–110 | X17290 |
| MBP1 [25] | TCCAGACGCGACTATCCTTCTCCC | 356–333 | X17289 |

Table 2 Overview PCR assays performed on the extracted RNA from brain tissue

| Assay | Forward primers | Reverse primers |
|-------|-----------------|-----------------|
| MBP   | MBP1            | MBP3            |
| HCV-229E I | CORO1            | CORO2            |
| HCV-229E II | CORO3            | CORO4            |
| HCV-229E III (nested) | CORO1, CORO9 | CORO2, CORO10 |
| HCV-229E IV | E7              | E9              |
| HCV-OC43 V | CORO5            | CORO6            |
| HCV-OC43 VI (nested) | CORO5, CORO11 | CORO6, CORO12 |
| HCV-OC43 VII | O7               | O9               |

Cycle sequencing was performed according to the manufacturer’s instructions (Perking Elmer Applied Biosystems, California, USA) with [\(\alpha\)-33P]dATP as radioactive label. The reactions were performed according to the manufacturer’s instruction. Electrophoresis was run on a polyacrylamide gel. The gels were dried on filter paper and X-ray films were used to visualize the radioactive bands on the dried gel.

Results

A total of 97 specimens from 61 individuals were assayed in 1063 RT-PCR assays (173 specific for MBP mRNA, 416 for HCV-229E and 474 for HCV-OC43). Twenty-one specimens had an \(A_{260}/A_{280}\) ratio lower than 1.6, and 4 of these were also negative for MBP. These 21 specimens were excluded, and only the results of the remaining 76 specimens are described. The 76 specimens yielded a mean of 105 µg RNA/g brain tissue, which is slightly lower than the 200–600 µg/g reported in the literature using the same method of extraction [10, 14, 21]. One MS patient was completely excluded as no RNA was detectable in any of the samples extracted. The sensitivity of the assays were in the range of below 10 for the nested PCR assays to 100 Tissue culture infective doses.
Fig. 1  Results of a nested PCR assay III for HCV-229E. Lanes 14 and 23 are positive specimens. Lanes 26 and 27 are positive controls amplified from 3 μl of supernatant fluid with a TCID₅₀ of 10⁹/ml diluted 10⁻¹ and 10⁻³. Lanes 28–30 are sterile water controls. The PCR products were of the expected 309 base pairs, were positive on hybridization with the specific probe and yielded the expected DNA sequence.

Table 3  Results of the first specimen tested from each patient. Thus each patient or control is counted only once with the result of one test for comparison. Fishers exact test $P=0.55$ (MS multiple sclerosis).

| Number of patients | MS (40%) | Controls (29%) | Total (32%) |
|--------------------|----------|----------------|------------|
| Positive in at least one PCR assay | 7        | 10             | 17         |
| Negative in all PCR assays | 12       | 24             | 36         |
| Total               | 19       | 34             | 53         |

Of the specimens tested, 32% were positive in at least one assay. An example of a PCR result is shown in Fig. 1. For comparison between the MS group and controls each individual was counted only once using the first specimen extracted and assay performed (Table 3). In one nested PCR assay for HCV-229E, 31% of the patients were found positive. These results could not be reproduced by repeating the same PCR or on the other PCR analyses, neither on the same or different specimens. These PCR products were sequenced and found identical to the expected sequence from the human coronaviral nucleocapsid gene. There was no proportional difference in these sporadic positive signals between the MS group and controls. No patient or control was consistently positive, neither on reanalysis of RNA from the same extraction or on the other PCR analyses, found positive. These results could not be reproduced by both HCV-OC43 and HCV-229E. No simple technical explanation can be found for these inconsistent positive signals. One explanation could be a very low level presence of coronaviral target gene in only some of the specimens. If very few (in the order of 10⁻¹ or less) copies of the target gene are present the initiation of amplification in a PCR process becomes problematic. This is due to the probability of a target gene copy being present in aliquot and the probability of the primer annealing to the specific template. A low level presence of coronaviruses in the human brain could be possible after an ordinary episode of common cold due to coronaviruses. In animal models murine coronaviruses have been found to enter the brain of mice, rats and owl monkeys after intranasal inoculation [3, 5, 19, 20] and both a hematogenous spread and direct entry via the olfactory nerve has been found.

False positive results due to contamination cannot be ruled out, but extensive precautions were taken to avoid contamination [13] and UNG carry over prevention was used in some of the assays. The negative controls interspersed between the patient samples were consistently negative.

When comparing the results of the present study with the literature (Table 4) we have found a higher frequency of positives in the control group than previously reported. This could be a bias in the previous studies due to more specimens/assays recorded in the groups of patients with MS. The two studies describing HCV genome in the human brain tissue have both counted all the patients with at least one positive signal, disregarding negative results of repeat specimens [16, 25]. Murray et al. [15] used in situ hybridization techniques and found 52% of the patients with MS positive, but only 11% of the 442 sections examined were positive. In the control group 0.8% of 376 sections were positive. In the positive sections only few cells were positive. This study is comparable to the present study in regards to the paucity of the positive signals observed. Talbot et al. [25] have examined 21 specimens...
from 11 patients with MS and 11 specimens from 11 controls. Not all samples from the positive patients were found positive for HCV-229E. However, the results from the positive specimens were reproducible in contrast to the present study. Weighted pooling of the data (Table 4) shows that more patients with MS were positive compared to controls. This estimate could be biased, as negative studies are less likely to be published [8].

The present results do not provide evidence for a chronic infection with the human coronaviruses strain 229E or OC43 in brain tissue from patients with MS or controls. However, few positive signals were found, which could be spurious contamination, but low level viral expression of in brain tissue cannot be ruled out.

Acknowledgements Financial support was provided by the Scleroforeningen (The Danish Multiple Sclerosis Society), the “Di rektor Ejnar Jonasson, kaldet Johnsen og hustru’s” foundation, and roseforeningen (The Danish Multiple Sclerosis Society), the “Warwara Larsens” foundation. The project was approved by the Ethics Committee of Copenhagen County, Denmark. Nathalie Arbour and Pierre J. Talbot (Institut Armand-Frappier, Université de Québec, Québec, Canada) provided the positive control strains and some of the primer sequences. Jørgen Clausen, Institute of Life Sciences and Chemistry, Roskilde University, Denmark is thanked for providing brain tissue samples from patients with MS.

References

1. Arbour N, Bonavia A, Yong VW, Newcombe J, Dessau RB, Talbot PJ (1996) Human coronaviruses and multiple sclerosis: detection by RT-PCR in human brains and infection of primary cultures of neural cells. Abstracts of the Xth International Congress of Virology, Jerusalem
2. Armitage P, Berry G (1987) Further analysis of qualitative data. In: Statistical methods in medical research. Blackwell, Oxford, pp 371–407
3. Barthold SW, Smith AL (1992) Viremic dissemination of mouse hepatitis virus-JHM following intranasal inoculation of mice. Arch Virol 122:35–44
4. Burks JS, DeVald BL, Jankovsky LD, Gerdes JC (1980) Two multiple sclerosis patients. Science 209:933–934
5. Cabirac GF, Soike KB, Zhang JY, Hoel K, Butuno C, Cai GY, Johnson S, Murray RS (1994) Entry of coronavirus into primary CNS following peripheral infection. Microbiol Pathog 16: 349–357
6. Dessau RB (1997) Coronaviruses in patients with multiple sclerosis. PhD thesis, Faculty of Health Sciences, University of Copenhagen, Copenhagen
7. Dessau RB, Lisby G, Frederiksen JL (1999) Coronaviruses in spinal fluid of patients with acute monosymptomatic optic neuritis. Acta Neurol Scand 100:88–91
8. Dickersin K, Min YI (1993) NIH clinical trials and publication bias. Online J Curr Clin Trials Doc No 50
9. Fazakerley JK, Buchmeier MJ (1993) Pathogenesis of virus-induced demyelination. Adv Virus Res 42:249–324
10. Johnson SA, Morgan DG, Finch CE (1993) Extensive post-mortem stability of RNA from rat and human brain. J Neurosci Res 16:267–280
11. Kamahora T, Soe LH, Lai MMC (1989) Sequence analysis of nucleocapsid gene and leader RNA of human coronavirus OC43. J Gen Virol 70:133–137
12. Kurtzke JF (1993) Epidemiologic evidence for multiple sclerosis as an infection. Clin Microbiol Rev 6:382–427
13. Kwok S, Higuchi R (1989) Avoiding false positives with PCR. Nat Med 33:237–238
14. Leonard S, Logel J, Luthman D, Casanova M, Kirch D, Freedman R (1993) Biological stability of mRNA isolated from human postmortem brain collections. Biol Psychiatry 33:456–466
15. Murray RS, Brown B, Brian D, Cabirac GF (1992) Detection of coronavirus RNA and antigen in multiple sclerosis brain. Ann Neurol 31:525–533
16. Murray RS, Cai GY, Hoel K, Johnson S, Cabirac GF (1993) Coronaviruses and multiple sclerosis. Adv Exp Med Biol 342: 353–357
17. Myint SH (1995) Human coronavirus infections. In: Siddell SG (ed) The Coronaviridae. Plenum Press, New York, pp 389–401
18. Noguchi I, Arai H, Isaka R (1991) A study on postmortem stability of vasopressin messenger RNA in rat brain compared with those in total RNA and ribosomal RNA. J Neural Transm 83:171–178
19. Perlman S, Jacobsen G, Moore S (1988) Regional localization of virus in the central nervous system of mice persistently infected with murine coronavirus IHM. Virology 166:328–338
20. Perlman S, Jacobsen G, Alfie A (1989) Spread of a neurotropic murine coronavirus into the CNS via the trigeminal and olfactory nerves. Virology 170:556–560
21. Perrett CW, Marchbanks RM, Whatley SA (1988) Characterisation of messenger RNA extracted post-mortem from the brains of schizophrenic, depressed and control subjects. J Neurol Neurosurg Psychiatry 51:325–331
22. Sambrook J, Fritsch EF, Maniatis T (1990) Molecular cloning. A laboratory manual. Cold Spring Harbor Laboratory Press, New York, pp 7.19–7.21
23. Schreiber J, Kamahora T, Lai MMC (1989) Sequence analysis of the nucleocapsid gene of human coronavirus 229E. Arch Virol 122:35–44
24. Southern EM (1975) Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol 98:503–505
25. Stewart JN, Mounir S, Talbot PJ (1996) Human coronavirus gene expression in the brains of multiple sclerosis patients. Virology 191:502–505
26. Streicher R, Stoffel W (1989) The organization of the human myelin basic protein gene – comparison with the mouse gene. Biol Chem Hoppe-Seyler 370:503–510
27. Wege H (1998) Immunopathological aspects of coronavirus infections. Springer Semin Immunopathol 17:133–148

Table 4 Evidence of coronavirus particles, isolates or genome in brain tissue reported in the literature and in the present study. The virus strains detected are marked with bold and underlined.

| Year and Reference | Methods: virus strains | MS patients | Controls |
|--------------------|------------------------|------------|---------|
| 1980 [4]           | Culture: SD, SK        | 2/13       | 0/13    |
| 1992 [15]          | In situ hybr.: MHV-A59, SD, OC43, BCV, 229E, TGEV, HSV | 12/21 | 2/21 |
| 1992 [25]          | PCR: HCV-OC43, HCV-229E | 4/11 | 0/11 |
| Present*           | PCR: HCV-OC43, HCV-229E | 7/19 | 10/34 |
| Crude pooling of data |                        | 25/64 | 12/79 |

*Data from the present study from Table 3. Combination of the tables using weighted mean and 95% confidence intervals for the pooled differences: 26%, 12–40%, P<0.001 [2]